Update on the use of radiopharmaceuticals for positron emission tomography imaging of prostate cancer Actualización del uso de radiofármacos en tomografía por emisión de positrones en el cáncer de próstata

Adenocarcinoma of the prostate is the most frequent neoplasm in men, with 50% of males over the age of 70 years presenting this type of cancer. In addition, it is the second cause of oncological death.1 The diagnosis of prostate cancer is well established, being based on the determination of the prostate-specific antigen (PSA), rectal tact, transrectal echography and prostate gland biopsy. The performance of a biopsy is guided by the echographically suspicious image but should be randomly performed by sextants to collect a sufficient number of samples from each lobe.2